SG Americas Securities LLC Boosts Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

SG Americas Securities LLC raised its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 188.5% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 60,202 shares of the company’s stock after purchasing an additional 39,335 shares during the quarter. SG Americas Securities LLC’s holdings in Xeris Biopharma were worth $172,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in XERS. Simplicity Wealth LLC purchased a new position in shares of Xeris Biopharma in the 2nd quarter worth $27,000. Allspring Global Investments Holdings LLC grew its position in Xeris Biopharma by 4,512.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 16,282 shares of the company’s stock worth $37,000 after acquiring an additional 15,929 shares in the last quarter. Bayesian Capital Management LP purchased a new position in Xeris Biopharma in the first quarter worth about $37,000. Asset Management Group Inc. increased its stake in Xeris Biopharma by 130.7% during the second quarter. Asset Management Group Inc. now owns 26,480 shares of the company’s stock worth $60,000 after acquiring an additional 15,000 shares during the last quarter. Finally, Sanctuary Advisors LLC purchased a new stake in Xeris Biopharma during the second quarter valued at approximately $75,000. Institutional investors own 42.75% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Xeris Biopharma in a report on Thursday, August 15th.

Xeris Biopharma Trading Up 3.0 %

Xeris Biopharma stock opened at $3.11 on Thursday. Xeris Biopharma Holdings, Inc. has a 12-month low of $1.46 and a 12-month high of $3.26. The firm has a 50-day moving average price of $2.84 and a 200-day moving average price of $2.37. The firm has a market capitalization of $461.08 million, a PE ratio of -6.43 and a beta of 2.76.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. The business had revenue of $48.07 million during the quarter, compared to the consensus estimate of $46.80 million. Xeris Biopharma had a negative net margin of 32.83% and a negative return on equity of 16,662.63%. During the same quarter last year, the firm earned ($0.14) earnings per share. As a group, sell-side analysts predict that Xeris Biopharma Holdings, Inc. will post -0.4 earnings per share for the current fiscal year.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.